

AWARD NUMBER: W81XWH-19-1-0359

TITLE: Roles of Lymphatic Vessels in Cardiac Tissue Regeneration

PRINCIPAL INVESTIGATOR: Ching-Ling Lien, Ph.D.

CONTRACTING ORGANIZATION: Children's Hospital Los Angeles

REPORT DATE: May 2022

TYPE OF REPORT: Final Technical Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE MAY 2022			2. REPORT TYPE Final Technical Report		3. DATES COVERED 15JUL2019 - 14JAN2022	
4. TITLE AND SUBTITLE Roles of Lymphatic Vessels in Cardiac Tissue Regeneration					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER W81XWH-19-1-0359	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Ching-Ling Lien E-Mail: clien@chla.usc.edu					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Children's Hospital Los Angeles 4650 Sunset Blvd. MS#137 Los Angeles, CA 90027					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Heart failure is the leading cause of death in the US and globally. There is a pressing need for novel therapeutic interventions to prevent heart failure in patients with coronary heart diseases. Tissue regeneration holds great promise of treating organ injuries and chronic diseases, including coronary heart disease. We proposed to investigate the roles of cardiac lymphatic vessels in revascularization and immune cell modulation, two processes important for heart regeneration. Our preliminary data suggest that cardiac lymphatic vessels can carry blood and perfuse myocardium of zebrafish, an animal with remarkable capacity of heart regeneration. These cardiac lymphatic vessels form in close association with coronary arteries, and this morphology is conserved with human hearts. We also found that hearts with impaired cardiac lymphatic vessels fail to regenerate. Furthermore, we discovered sex and injury model dependent mechanisms of cardiac lymphatic vessel formation and its role in heart repair and regeneration. These molecular mechanisms underlying cardiac lymphatic vessel formation after heart injury might lead to development of novel therapeutic designs for myocardial revascularization and regeneration.						
15. SUBJECT TERMS Heart Regeneration, Cardiac Lymphatic Vessels, revascularization,						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON	
a. REPORT	b. ABSTRACT	c. THIS PAGE	Unclassified	14	USAMRDC	
Unclassified	Unclassified	Unclassified			19b. TELEPHONE NUMBER (include area code)	

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	5
3. Accomplishments	6
4. Impact	11
5. Changes/Problems	12
6. Products	13
7. Participants & Other Collaborating Organizations	14
8. Special Reporting Requirements	16
9. Appendices	17

1. INTRODUCTION

The lymphatic vasculature is a specialized network of vessels that drains fluid from tissues and enables immune-cell trafficking and surveillance throughout the body. How lymphatic vessels affect tissue regeneration is not well understood. After ischemic heart injuries, myocardial edema decreases cardiac output and can cause interstitial fibrosis. In addition to fluid homeostasis and immune cell surveillance, our unexpected findings suggest that zebrafish cardiac lymphatic vessels can carry red blood cells and perfuse the myocardium in zebrafish. Zebrafish provide a unique opportunity to study the roles of lymphatic vessels after tissue injuries. They have remarkable regenerative capacity after traumatic injuries. Available forward and reverse genetic mutants and transgenic lines make detailed molecular imaging and mechanistic studies possible. Furthermore, well established injuries models for different zebrafish organs allow us to test different injury types and severities even for the same organ. Our data suggest that new cardiac lymphatic vessels form in response to cryoinjury, a model mimicking the pathogenesis of myocardial infarction. Furthermore, zebrafish with impaired cardiac lymphatic vessels fail to regenerate their hearts after cryoinjury. We have examined the roles of lymphatic vessels in revascularization and immune cell trafficking, two processes that are important for fibrotic scar resolution and cardiac regeneration. We discovered a sex-dependent difference in cardiac lymphatic vessel formation. We are still assessing how this difference affects the responses of males and females to heart injuries. Furthermore, we found that even though *ackr3a* mutants show increased cardiac lymphatic vessels, enhanced immune cell clearance, and decreased fibroblast activation after a cryoinjury to the heart, these mutants displayed defects in coronary vessel formation after a resection injury to the heart. We are continuing to determine the cross-talk between coronary and cardiac lymphatic vessels to elucidate how different sex and injury models induce different injury and regenerative responses in the hearts.

2. KEYWORDS

Heart regeneration

Cardiac lymphatic vessel

revascularization

fibrotic scar resolution

Immune cell trafficking

zebrafish

3. ACCOMPLISHMENTS

Project Goals.

1. To determine how cardiac lymphatic vessels affect myocardial revascularization?

We will investigate whether blood perfusion through cardiac lymphatic vessels increases in response to physiological stress or after heart amputation or cryoinjuries. These experiments will elucidate how lymphatic vessels might affect revascularization after different types of heart injuries.

2. To determine how cardiac lymphangiogenesis affect myocardial regeneration and scar resolution

We will ablate the lymphatic vessels to observe how myocardial regeneration is impacted after heart amputation or cryoinjuries. We will also utilize an *ackr3a* fish mutant that displays increased lymphatic vessels to evaluate whether they have enhanced myocardial regeneration. These experiments will shed light on how lymphatic vessels might regulate fibrotic scar resolution and myocardial regeneration after different type of injuries.

Major Activities 1 (Major Task 1 in SOW): Determine blood perfusion and revascularization via cardiac lymphatic vessels occur in response to physiological stress or heart injury

1. Revascularization by cardiac lymphatic vessels during zebrafish heart regeneration

We validated our preliminary data and use a different transgenic reporter line (*lyve1:GFP*) that marks cardiac lymphatic vessels and observed that *gata1:dsRed*⁺ erythrocytes are present in cardiac lymphatic vessels at one day post heart cryoinjury (dpc) (Figure. 1). These erythrocytes are absent in cardiac lymphatic vessels in uninjured hearts.




Figure. 1. Zebrafish cardiac lymphatic vessels carry erythrocytes in response to heart injuries. Erythrocytes (red blood cells) were marked with *gata1*, Red; lymphatic vessels were marked with *lyve1*, Green. Images of uninjured heart (Un-amp, left), heart at 1 day post amputation (1dpa, right). N=3 each for uninjured and 1 dpa.

2. Sex dependent cardiac lymphatic vessel formation. It was shown recently that cardiac lymphangiogenesis after myocardial infarction in mice shows sex-dependent differences. We also observed large variations in the coverage of cardiac lymphatic vessels when we characterized cardiac lymphatic vessel growth. To better understand the factors affecting cardiac lymphatic growth and reduce the variation in our analyses, we investigated if sex is one of the factors that affects the formation of cardiac lymphatic vessels. The cardiac lymphatic vessels were labeled by *lyve1b:dsRed* or *flt4:mCitrine* in zebrafish and the hearts from size-matched female and male fish were harvested and imaged at 5 mpf (months post fertilization) and 8 mpf. As shown in

Figure 2, male fish had a significant increase in cardiac lymphatic vessels compared to age and size matched female fish in both 5 mpf and 8 mpf groups. Approximately 60% of female fish showed no or delayed cardiac lymphatic vessel outgrowth by 5 mpf while all male fish had cardiac lymphatic vessels appeared on the ventricles. Both female and male fish had cardiac lymphatic vessels on the heart ventricles at 8 mpf but male fish had significantly more cardiac lymphatic vessel coverage. This sex-dependent difference is affecting our phenotyping and quantification for the results in 1. However, the significant implication is that cardiac lymphatic vessels might also account for the sex-dependent difference in coronary heart diseases. We are currently investing whether *ackr3a* mutant phenotypes are also affected in a sex-dependent manner.




Figure 2. Male zebrafish showed increased cardiac lymphatic vessel growth. A) The representative images of female and male hearts at 5mpf and 8mpf carrying transgenic reporter. The endothelial cells were labelled by *fli:GFP* in green and the lymphatic endothelial cells were labelled by *lyve1b:dsRed* in Red in 5mpf groups. The arterial endothelial cells were labelled by *flt1:tdTomato* in Red and the lymphatic endothelial cells were labelled by *flt4:mCitrine* in Yellow in 8mpf groups. B) The quantification of cardiac lymphatic coverage of A). Cardiac lymphatic vessel coverage was quantified as the percentage of the amount of cardiac lymphatic vessels on the entire ventricle. The data was present in mean+SEM in the panel. N=5 each for males and females.

Major Activities 2 (Major Task 2 in SOW): Determine new lymphatic vessel formation is beneficial to heart regeneration

Subtask 2: Determine immune cell trafficking via cardiac lymphatic vessels.

ackr3a mutant hearts have better immune cell clearance compared to WT controls after cryoinjury

To investigate if increased cardiac lymphatic vessels in *ackr3a* mutants play a role in immune cell transport, neutrophils and macrophages in *ackr3a* mutants and WT controls were stained in whole mount with Mpx and IB4 antibodies at 0, 1, and 7 days post cryoinjury (dpc) (Figure 3). At 0 dpc, both *ackr3a* mutants and WT controls only had few immune cells on the ventricles. At 1 dpc, *ackr3a* mutants and WT controls had a severe inflammatory response after cryoinjury and recruited large number of neutrophils and macrophages to the whole ventricles. However, at 7dpc, *ackr3a* mutants nearly cleared all neutrophils and macrophages,




Figure 3. *ackr3a* mutant hearts have better immune cell clearance compared to WT controls after cryoinjury. (A) A representative image with Mpx and IB4 antibody staining at 0 (A, B), 1 (C, D) and 7 dpc (E, F). (A, B) Both WT controls and *ackr3a* mutants have few immune cells on the ventricles before injury. (C, D) WT controls and *ackr3a* mutants recruited neutrophils and macrophages on the whole ventricle at 1dpc. (E, F) At 7 dpc, *ackr3a* mutants nearly cleared all neutrophils and macrophages on the ventricles. (n=6)

while WT controls still had some neutrophils and macrophages remaining at wound sites. With more cardiac lymphatic vessels, *ackr3a* mutant hearts had better clearance of immune cells after cryoinjury.

4. Fibroblast activation was reduced in *ackr3a* mutants after cryoinjury.

To investigate if Ackr3a affects fibroblast activation in heart regeneration, cryoinjury was performed in 8-month-old *ackr3a* mutants and WT control fish with *wt1a:GFP* and *postnb:Citrine* reporters. Fibroblast activation was indicated by the co-expression of *wt1a:GFP* (which marks cardiac fibroblasts) and *postnb:Citrine* (which marks myofibroblasts). The expression of both *wt1a:GFP* and *postnb:Citrine* were reduced at the wound area in 10 dpc *ackr3a* mutants (Figure 4). These results suggest that *ackr3a* mutants might form less scar tissue due to decreased fibroblast activation after heart injury.




Figure 4. Fibroblast activation was reduced in *ackr3a* mutants after cryoinjury. A) Representative image of cryoinjured WT fish heart with *wt1a:GFP* and *postnb:Citrine* at 10dpc. The co-expression of *wt1a:GFP* and *postnb:Citrine* indicates the fibroblast activation. A') The single channel of *postnb:Citrine* of A). B) Representative image of cryoinjured *ackr3a* mutant fish heart with *wt1a:GFP* and *postnb:Citrine* at 10dpc. B') The single channel of *postnb:Citrine* of B). n = 3 each for *ackr3a* mutants and controls.

Ackr3a is required for heart regeneration after amputation.

In order to investigate the role of Ackr3a in heart regeneration, amputation at the ventricle apex was performed in 8 month-old *ackr3a* mutant and WT control fish. The heart regeneration process was then examined by AFOG staining 30 days post amputation (dpa). In contrast to the results observed after a cryoinjury, 6 out of 8 *ackr3a* mutants hearts failed to regenerate and left a big scar at the injury site. By comparison, 7 out of 7 WT fish completely finished the heart regeneration process at 30 dpa (Figure 5). These data suggest that Ackr3a is required for heart regeneration after amputation.




Figure 5. Ackr3a is required for heart regeneration after amputation. A) AFOG staining of WT heart at 30dpa. Scar tissue was resolved and lost cardiomyocytes was replaced in the wound area at 30dpa B) AFOG staining of *ackr3a* mutant heart at 30dpa. Large scar tissues remain at wound area in most *ackr3a* mutants. C) Percentage of hearts with or without scar at 30dpa in WT and *ackr3a* mutants.

3. Ackr3a is required for coronary vessel revascularization after amputation.

To investigate the cause of regenerative failure in *ackr3a* mutants after amputation, we examined if Ackr3a also affects coronary vessel revascularization after amputation. The apexes of heart were imaged at 30 dpa in *ackr3a* mutants and WT controls using the *fil1a:EGFP* endothelial reporter. At this stage, WT hearts already completed the revascularization process and had dense blood vessels formed covering the wound area. In contrast, new vessel formation is completely blocked in 7 out of 8 hearts in *ackr3a* mutants (Figure 6). These results further suggest that Ackr3a is required for heart regeneration after amputation by regulating coronary vessel revascularization.




Figure 6. *Ackr3a* is required for coronary vessel revascularization after amputation. A) WT heart apex image at 30dpa. Newly formed coronary vessels completely covered the injury site at 30dpa B) *ackr3a* mutant heart apex image at 30dpa. The revascularization was blocked in *ackr3a* mutant at 30dpa C) Percentage of hearts with or without coronary vessel revascularization at wound area at 30dpa in WT controls and *ackr3a* mutants.

3. Single cell RNAseq analyses comparing *ackr3a* mutants and controls. To further elucidate the molecular mechanisms of cardiac lymphatic vessel formation and how they might carry erythrocytes, we performed single cell RNAseq using whole heart samples to compare *ackr3a* mutants (n=5 hearts) and controls (n=5 hearts). We identified distinct clusters of different cell types of cardiomyocytes, immune cells, epicardial and endothelial cells, and lymphatic endothelial cells account for a small cluster (Figure 7). We are currently comparing these populations between *ackr3a* mutants and sibling controls.




Figure 7. Single cell RNAseq analysis comparing *ackr3a* mutants and controls. Integrative UMAP shows different cell types identified in *ackr3a* mutants and WT controls. Feature plots *flt4* indicate that cluster 14 is the lymphatic endothelial cells.

What opportunities for training and professional development has the project provided?

Dr. Michael Harrison, a postdoctoral associate in the lab, has worked on this project. He has gained knowledge and research experience in the area of lymphatic development and heart regeneration. Dr. Harrison has completed his postdoctoral training in my laboratory and our institute and departed on Aug. 15, 2020 to establish his own independent laboratory at Weill Cornell Medical College.

Dr. Stanislao Travisano, a postdoctoral fellow, has continued the study after Dr. Harrison's departure. He has learned the techniques working with zebrafish and knowledge related to cardiac lymphatic vessels. He has also attended workshops and training on single cell analyses and is analyzing our datasets.

How are the results disseminated to communities of interest?

1.The research results were presented as progress reports as weekly seminars at the Program of Developmental Biology and Regenerative Medicine, Saban Research Institute, Children's Hospital Los Angeles

2.The research results were presented at the Gordon Research Conference on Lymphatics by Dr. Ching-Ling Lien

What do you plan to do during the next reporting period to accomplish the goals?

Nothing to report.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

1. This project will reveal a new mechanism by which cardiac lymphatic vessels regulate immune cell clearance and fibrotic scar resolution of regenerating zebrafish hearts.
2. This project will reveal a novel mechanism by which cardiac lymphatic vessels regulate revascularization of regenerating zebrafish hearts.
3. The project might identify novel candidate genes to enhance cardiac lymphatic vessel formation.

What was the impact on other disciplines?

Nothing to report

What was the impact on technology transfer?

Nothing to report

What was the impact on society beyond science and technology?

Nothing to report

5. CHANGES/PROBLEMS

Change in approach and reasons for change

Nothing to report

Actual or anticipated problems or delays and actions or plan to resolve them

The proposed experiments and milestones were delayed due to COVID-19. We resumed research activities after our research institute re-opened but the work schedule was significantly affected due to our institute's social distance requirement. We maintained 25-30% personnel in the lab space at a given time from July 15, 2020 until March 1, 2022.

Changes that had significant impact on expenditures

Due to COVID-19 related delays, we have not been able to place purchase requisitions required for the experiments for a few months and many purchase requisitions were also back ordered. Therefore, we have less expenditure than proposed.

Significant changes in use or care of human subjects, vertebrate animals, biohazards and/or select agents

Nothing to report

6. PRODUCTS

Publications, Conference papers, and presentation

Feng X, Travisano S, Pearson, CA, **Lien CL*** and Harrison MRM*. The lymphatic system in zebrafish heart development, regeneration, and disease modeling. J. Cardiovasc. Dev. Dis. 8(2):21 (2021). * Co-Corresponding (see attached appendices).

Other publications, conference paper and presentations.

The role of cardiac lymphatic vessels in zebrafish heart development and regeneration. Ching-Ling (Ellen) Lien presented at Lymphatics, Gordon Research Conference, The Growth and Function of Therapeutic Targeting During Development and Disease, March 1-6, 2020. Ventura, CA (see attached abstract).

Websites or other internet sites

Nothing to report

Technologies or techniques

Nothing to report

Inventions, patent applications, and/or licenses

Nothing to report

Other products

Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name	Ching-Ling (Ellen) Lien, Ph.D.
Project Role	Project Director/Principal Investigator
Researcher Identifier (e.g. ORCID ID)	0000-0002-5100-9780
Nearest person month worked	1.2 calendar
Contribution to Project	Dr. Lien is the PI of this project and oversees the overall direction, data collection, analysis and completion of milestones of the project. She oversees the project goals are accomplished in a rigorous and timely manner.
Funding support	NIH, TRDRP,
Name	Michael Harrison, Ph.D.
Project Role	Postdoctoral Research Associate
Researcher Identifier (e.g. ORCID ID)	0000-0003-1703-9879
Nearest person month worked	8 calendar (until Aug. 2020)
Contribution to Project	Dr. Harrison has performed heart injuries, tissue collection, confocal imaging and data analysis of the project
Funding support	None
Name	Stanislao Travisano, Ph.D.
Project Role	Postdoctoral fellow
Researcher Identifier (e.g. ORCID ID)	0000-0003-1703-9879
Nearest person month worked	6 calendar (after Aug. 2020)
Contribution to Project	Dr. Travisano has performed heart injuries, tissue collection, confocal imaging and data analysis of the project
Funding support	None

Has there been a change in the active other support of the PD/Pis or senior/key personnel since the last reporting period?

Dr. Ching-Ling Lien has received two new grants since 07/01/2019:

T30IP1028 (Lien, PI) 09/02/2019-08/31/2021 1.2 calendar
California Tobacco Related Disease Research Program (TRDRP) Annual DC Title:
“Effects of tobacco and e-cigarettes on heart repair and regeneration”

Description: The goal of this high-impact pilot research award is to determine the effects of tobacco and e-cigarettes on heart repair and regeneration. Both adult zebrafish and neonatal mice will be used as heart regeneration models.

There is no scientific overlap between this project and the current DoD project.

Role: PI

Grant No. 1R01HL148706-01A1 Lien (PI) 08/28-20-05/31/24 3.6 calendar
Agency NIH(NHLBI) Annual DC Title:

Cardiac lymphatic vessels in heart development and regeneration

Description: The goals of this grant are to determine mechanisms of Cxcl12-Cxcr4a-Ackr3a-Stat4 signaling in regulating cardiac lymphatic vessel formation in association with coronary arteries. Although Ackr3a has been reported in mediating Adrenomedullin signaling in regulating cardiac lymphatic vessels, we propose that it also functions as a decoy receptor of Cxcr4a to guide the association of cardiac lymphatic vessels with coronary arteries.

There is no scientific overlap between this project and the current DoD project.

Role: PI

What other organizations were involved as partners?

None

8. SPECIAL REPORTING REQUIREMENTS

Collaborative Awards: Not Applicable

Quad Charts: Not Applicable

9.APPENDICES

1. Lymphatics, Gordon Research Conference, The Growth and Function of Therapeutic Targeting During Development and Disease, March 1-6, 2020. Ventura, CA.

Abstract

CARDIAC LYMPHATIC VASCULATURE SUPPORTS ZEBRAFISH HEART DEVELOPMENT AND REGENERATION

Michael RM Harrison, Xidi Feng, Joycelyn K. Yip, Megan L. McCain, Matthew Thornton, Brendan Grubbs, Stefan Schulte-Merker and Ching-Ling Lien

The cardiac lymphatic vascular system and its potentially critical functions in hearts have been largely underappreciated. We demonstrate that cardiac lymphatic vessels develop in young adult zebrafish using coronary arteries to guide their expansion down the ventricle. Mechanistically, we show that in *cxc4a* mutants with defective coronary artery development, cardiac lymphatic vessels fail to expand onto the ventricle. Interestingly, we observed similar arterial association of cardiac lymphatic vessels in human fetal hearts, whereas they mainly associate with cardiac veins in embryonic mouse hearts. This finding suggests that the zebrafish heart provides a unique model to study cardiac lymphatic vessel development relevant to human biology. In regenerating adult zebrafish hearts, the lymphatic vasculature undergoes extensive lymphangiogenesis in response to a cryoinjury with more necrotic tissue and prolonged inflammation at the wound site. A significant defect in reducing scar size after cryoinjury is observed in zebrafish with impaired *Vegfc/Vegfr3* signaling that fail to develop intact cardiac lymphatic vessels. These results suggest that the cardiac lymphatic system can influence the regenerative potential of the myocardium. We are currently generating new CRISPR fish mutants and utilizing our live-imaging platform to further investigate the cellular and molecular mechanisms of cardiac lymphatic vessel expansion.

2. Publication: Feng X, Travisano S, Pearson, CA, **Lien CL*** and Harrison MRM*. The lymphatic system in zebrafish heart development, regeneration, and disease modeling. *J. Cardiovasc. Dev. Dis.* 8(2):21 (2021).
* Co-Corresponding (see attached).



Review

The Lymphatic System in Zebrafish Heart Development, Regeneration and Disease Modeling

Xidi Feng^{1,†}, Stanislao Travisano^{1,†} , Caroline A. Pearson², Ching-Ling Lien^{1,3,4,*}
and Michael R. M. Harrison^{5,6,*}

¹ The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA 90027, USA; xidifeng@usc.edu (X.F.); stravisano@chla.usc.edu (S.T.)

² Laboratory of Neurogenetics and Development, Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY 10021, USA; cap4010@med.cornell.edu

³ Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

⁴ Department of Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

⁵ Cardiovascular Research Institute, Weill Cornell Medical College, New York, NY 10021, USA

⁶ Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10021, USA

* Correspondence: clien@chla.usc.edu (C.-L.L.); mrh4003@med.cornell.edu (M.R.M.H.)

† These authors contributed equally to this work.

Abstract: Heart disease remains the single largest cause of death in developed countries, and novel therapeutic interventions are desperately needed to alleviate this growing burden. The cardiac lymphatic system is the long-overlooked counterpart of the coronary blood vasculature, but its important roles in homeostasis and disease are becoming increasingly apparent. Recently, the cardiac lymphatic vasculature in zebrafish has been described and its role in supporting the potent regenerative response of zebrafish heart tissue investigated. In this review, we discuss these findings in the wider context of lymphatic development, evolution and the promise of this system to open new therapeutic avenues to treat myocardial infarction and other cardiopathologies.

Keywords: cardiac lymphatic vessels; zebrafish; heart; development; regeneration



Citation: Feng, X.; Travisano, S.; Pearson, C.A.; Lien, C.-L.; Harrison, M.R.M. The Lymphatic System in Zebrafish Heart Development, Regeneration and Disease Modeling. *J. Cardiovasc. Dev. Dis.* **2021**, *8*, 21. <https://doi.org/10.3390/jcdd8020021>

Received: 23 December 2020

Accepted: 11 February 2021

Published: 19 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1.1. The Lymphatic System: Discovery and Functions

In the 5th-century BC, Hippocrates described the presence of nodes containing a milky fluid (chyle) in specific subcutaneous and deep organ regions of the body [1]. Through the gallant efforts of a collection of anatomists, including Thomas Bartholin, Olaus Rudbeck and George Joyliffe, the “lymphatic vessels (*vasa lymphatica*)” were defined [1]. However, it was not until the 18th century, with the work of Mascagni and others, that it was appreciated that these lymph-containing vessels and nodes are an integral part of a network, which extends from blind-ended lymphatic capillaries (or initial lymphatics) to collecting lymphatic vessels that eventually connect to the blood circulatory system. In comparison to the blood circulatory system, understanding the role and development of the lymphatic system has been slow. This is in part due to the network being delicate and largely invisible in comparison to the obvious sphygmic blood circulatory system. The term lymph was coined to reflect this property coming from the Greek Nymph, a creature associated with clear streams and the Roman deity Lympha, meaning spring of clear water [1]. Even with the evolution of microscopy investigation, studies on the lymphatic system remained stubbornly hindered by a paucity of good molecular markers and labels. Nonetheless, just as blood vasculature is essential for the supply of oxygen and nutrients in addition to the removal of waste, the lymphatic vasculature also provides vital support of healthy tissue. As the range of techniques and technologies to study the lymphatic vasculature continues

to expand, so does our understanding of the unique and critical roles this system plays in tissue homeostasis and disease [2].

The lymphatic system provides a unidirectional conduit for the essential flow of fluid from the tissue interstitium back to the circulatory system. This fluid regulation is absolutely critical, and malformation (primary lymphedema) or disruption (secondary lymphedema) of lymphatic vessels results in disabling swelling of the tissue [3,4]. This lymph fluid is rich in plasma proteins and also contains immune cells and antigens. Through the various afferent lymphatics, lymph nodes are exposed to intact or degraded microorganisms and toxic stimuli [5]. These must be removed from the fluid before being returned to the blood flow, and recent studies suggest a population of neutrophils and macrophages in the lymphatic system prevent the systemic spread of tissue pathogens [6,7]. In addition to these innate immune cells, the lymphatic vasculature plays a critical role in supporting adaptive immune responses. Immune cells that ingest foreign antigens are brought into contact with lymphocytes in the node where they present antigens to activate the adaptive responses [5]. The lymphatic vessels are not just a passive conduit that is homogenous throughout the body, but they also have tissue-specific roles, including the active absorption of lipids and vitamins. Gut villi lymphatic vessels, called lacteals, take up dietary-fats as triglyceride particles known as chylomicrons packaged by the gut enterocytes [8]. These are then transported to the systemic blood system via collecting vessels and the thoracic duct [8]. As a result, lacteal control of lipid absorption has been implicated in obesity and its sequelae, including the impact on heart disease and function [9,10]. However, as we will discuss in this review, the lymphatic system also has an emerging direct role in supporting cardiovascular health and disease.

1.2. The Evolution of the Lymphatic System

Most invertebrates have an open circulatory system and no distinction between a lymphatic and blood system or their respective functions [11]. Vertebrates have a range of lymphatic system features, including lymphatic vessels, lymph nodes, lymphoid organs and tissues that appear to become increasingly distinct and specialized [12]. Jawless and cartilaginous fish lack lymphatic vessels; however, some thin-walled sinuses provide a conduit for extravascular fluid back into veins in these lower vertebrates [11]. In other vertebrates, lymphatic vasculature has contractile regions, which actively aid the flow of lymph into the venous circulation [11,13]. So-called lymph hearts have been identified in lungfish, amphibians, reptiles and some flightless birds. They are typically found at the junction between lymphatic and venous systems and have been lost in higher vertebrates [11,13]. A lymphatic system that often lacks a lymph heart similar to that of mammals is found in other species of bony fish (teleosts) [11]. However, the connection of this lymphatic system to the blood circulation appears to vary across teleosts species and organ systems. In trout and glassfish, an arterial connection to the blood system has been described, and the fluid of these secondary vasculature systems can become perfused with blood under hypoxic conditions [14]. Zebrafish have been shown to have an extensive lymphatic system throughout the body, and analyses of the zebrafish vasculature system suggest it shares many conserved anatomical features with the mammalian system [15,16]. The zebrafish system has bicuspid valves and a venous connection but lacks nodes [15,17]. The possibility that this lymphatic system also retains the ability to be perfused under extreme conditions has been contested [18–21]. Reflecting the systems increasing specialization, it is likely that a spectrum of blood and lymphatic vasculature interconnectedness exists across teleosts species. Nonetheless, the zebrafish has provided invaluable insight into the molecular regulation of lymphatic development and provides a fascinating evolutionary nexus to gain a deep understanding of lymphatic function in disease.

1.3. The Zebrafish Lymphatic System

The majority of research has focused on zebrafish lymphatic development during the embryonic stage, taking advantage of various transgenic and tracing tools and body

transparency. Lymphangiogenesis of the trunk lymphatic, facial lymphatic and intestinal lymphatic network has been well characterized in zebrafish embryos. The lymphangioblasts of trunk lymphatic vessels are derived from the posterior cardinal vein and migrate to the dorsal myoseptum to become parachordal lymphangioblasts by 2 days post-fertilization (dpf) [16,22–24]. Those lymphangioblasts migrate along intersomitic arteries dorsally and ventrally, forming intersomitic lymphatic vessels. The fish trunk lymphatic vasculature continues to develop to form the thoracic duct under the dorsal aorta and the dorsal longitudinal lymphatic vessel along the dorsal longitudinal anastomotic vessel by 5 dpf [15,16].

The development of facial lymphatic vessels starts from the budding of the lymphangioblasts from the common cardinal vein forming the facial lymphatic sprout (FLS) at 36 h post fertilization (hpf) [25,26]. The FLS migrate along the primary head sinus (PHS) towards the head area. The formation of facial lymphatic vessels is not from a single source of lymphangioblasts. As the FLS migrates, lymphangioblasts originating from the PHS and the ventral aorta join the FLS, making up a complex facial lymphatic network together.

The origin of intestinal lymphatics has not been identified. There is a large lymphatic vessel associated with the entire zebrafish intestine [26,27], indicating the intestinal lymphatics may also play a role in lipid transporting as in mammals. Unlike trunk lymphatic vessels that migrate along arteries, intestinal lymphatic vessels have been found to form along both arteries and veins. This suggests that there may be tissue-specific guidance cues that guide lymphatic endothelial cell (LEC) migration.

Although the development of the lymphatic system is well-studied in zebrafish embryos, the functional studies of lymphatic vessels in regeneration and disease models in different organs are in their infancy. In this review, we will discuss the recent work on zebrafish cardiac lymphatic vessels in heart regeneration and the implications of this for our understanding of the role of lymphatic vessels in heart disease.

2. The Development of the Lymphatic System

2.1. Venous and Non-Venous Origins

The lymphatic vasculature includes a network of LECs found in close proximity to, but separate from, the blood vasculature [28]. After carrying out ink-injection experiments in pig embryos, Florence Sabin hypothesized that the majority of lymphatic vessels bud off from the endothelium of the veins and that these primitive lymphatics then spread throughout the entire embryo body to create the lymphatic network. However, after injecting along the aorta, she also concluded that, despite budding from veins, the deep lymphatics follow arteries [29]. Cell lineage studies and grafting experiments in birds validated different sources of the lymphatic vascular system. The deeper parts of the jugular lymph sacs originate from the jugular segments of the cardinal veins and the superficial, dermal lymphatics from local lymphangioblasts in the dermatomes, while the LECs of the lymph heart is of somitic origin [30].

The first cardiac lymphatic described in the human embryo grows from two different plexuses. The first one near the left jugular lymph sac, elongating between the pulmonary trunk and the aorta and following the right coronary artery. The second plexus, described as the main one, terminates in the right jugular sac and follows the left coronary artery around embryonic week eight [31]. This is in contradiction to the mouse, in which the cardiac lymphatic vessels follow the course of the cardiac veins rather than the coronary arteries [32]. In zebrafish, the development of the cardiac lymphatics occurs during late juvenile to early adult stages after two months post-fertilization (mpf) when coronary arteries, not veins, provide a scaffold for the elongation of the lymphatic vessels and the expansion of the network [33,34]. This similarity between zebrafish and human cardiac lymphatic development could represent an ancestral mechanism of essential guidance cues for the cardiac lymphatic endothelium, which has been altered across mammalian species [35].

The lymphatic vasculature is thought to form exclusively by sprouting from embryonic veins (lymphangiogenesis). Lineage tracing experiments in mice embryos demonstrated that the lymphatic system has largely venous origins [36]. Time-lapse imaging in developing zebrafish embryos demonstrated that this process is well-conserved and that at least the main thoracic duct-like vessel arises embryonically from primitive veins [16]. However, the discovery of alternative non-venous origin(s) of LECs in mammals that contribute to the lymphatic vasculature of the skin [37], mesentery [38], and heart [32,39,40] has changed the understanding of the mechanisms of embryonic lymphatic vessel development. Furthermore, evidence of a non-venous lymphatic progenitor, named “ventral aorta lymphangioblast” (VA-L), was found to give rise to facial lymphatic in zebrafish, suggesting that the origin and development of lymphatic vessels is tissue context-dependent [41].

2.2. Molecular Mechanism of LEC Identity

The equilibrium between endothelial cell fate regulators, Notch, Coup-TFII (Nr2f2), and Prox1 may play a critical role in the specification of endothelial cell (EC) fate during vascular development and arteriovenous-lymphatic cell fate specification [42]. Notch signaling promotes arterial EC differentiation, while in venous ECs, Notch activity is repressed by the COUP-TFII orphan nuclear receptor to maintain the vein identity [43]. The specification of the LECs in mammals is dependent on PROX1, a key transcriptional factor also crucial for maintaining the lymphatic endothelial identity [44,45]. Transcription factors *Sox18* [46], *CoupTFII* [47], *Gata2* [48,49], and *Hhex* [50] have been found to regulate *Prox1* expression in mouse LECs.

LEC progenitors relocate from the cardinal vein through paracrine action of VEGF-C expressed by the neighboring mesenchyme to form the primitive lymph sacs [51,52]. LECs express VEGFR2 and VEGFR3, as well as the co-receptor neuropilin 2 (NRP2) [52,53]. It was also demonstrated that VEGF-C and VEGF-D act through VEGF receptor 3 (VEGFR-3) to induce lymphangiogenesis [54,55]. LYVE-1, one of the proteins expressed in mature LECs is also expressed in a subset of ECs from the large central veins and provides the first signal of lymphatic endothelial competence [56,57].

Similar to mammals, venous-derived lymphatic progenitors in zebrafish can be detected with *prox1a* expression [22,24], and lymphatic sprouting is reliant on *vegfr3* (known as *flt4* in zebrafish) [15,58]. However, the functionally related transcription factors Coup-TFII (Nr2f2) and Sox18 were found to be dispensable for lymphatic specification in zebrafish, suggesting that transcriptional regulation of lymphatic commitment may have diverged somewhat between zebrafish and mice [59]. However, it is not known if other Nr2f factors can compensate for the loss of Nr2f2.

3. The Development of Cardiac Lymphatic System in Zebrafish

A cardiac lymphatic vessel system in adult zebrafish has been identified [33,34,60] (Table 1). The zebrafish cardiac lymphatic vessels express common LEC markers discussed above, including *prox1a*, *lyve1b*, *flt4* and also *mrc1a* and *stab1* [33,34,60]. When cardiac LECs migrate, the very first 1–5 tip cells are primarily labeled by *flt4* [34]. Unlike mammals that develop their cardiac lymphatic vessels at embryonic stages, lymphatic vessels are found to develop in the zebrafish post-embryonically [33,34]. The zebrafish cardiac lymphatic vessels arise from ventral facial lymphatics, which migrate along the ventral aorta [34]. The cardiac lymphatic vessel sprouts are visible at the tip of bulbus arteriosus (BA) at 21–28 DPF before any coronary vasculature development on the zebrafish heart ventricle has occurred [33,34].

Table 1. Summary of the genetic tools and findings of papers describing the zebrafish cardiac lymphatic system.

	Vivien et al. [60]	Harrison et al. [33]	Gancz et al. [34]
Cardiac lymphatic vessels (LVs)	<i>prox1a⁺ lyve1b⁺</i>	<i>prox1a⁺ flt4⁺ lyve1b⁺</i> (high BA; low ventricle) <i>mrc1a⁺ stab1⁺</i>	<i>prox1a⁺ flt4⁺ lyve1b⁺ mrc1a⁺</i>
LVs in regeneration (cryoinjury)	<i>prox1a⁺</i>	<i>prox1a⁺ flt4⁺ lyve1b⁺</i> (low) <i>mrc1a⁺</i>	<i>prox1a⁺ flt4⁺ lyve1b⁺ mrc1a⁺</i>
Roles of LVs	Cardiac hypertrophy, metabolic homeostasis, and inflammation resolution	Cardiac regeneration, cell debris clearance and inflammation resolution	Cardiac regeneration
Mutants lacking BA LECs	<i>vegfc^{hy} -/- ; vegfd^{-/-}</i>	-	<i>flt4^{-/-}</i>
Mutants/Tg lacking ventricular LECs	<i>vegfc^{hy} +/- ; vegfd^{-/-}</i> <i>vegfc^{hy} -/- ; vegfd^{+/-}</i>	<i>sFlt4</i> <i>cxcr4a^{-/-}</i> (majority)	<i>vegfc^{+/-} , flt4^{-/-}</i> <i>cxcr4a^{-/-}</i> (isolated LECs unaffected)
Mutants with hypertrophy	<i>vegfc^{hy} -/- ; vegfd^{-/-}</i>	-	-
Mutants/Tg defective scar resolution	<i>vegfc^{hy} -/- ; vegfd^{-/-}</i> (30%)	<i>cxcr4a^{-/-}</i> <i>sFlt4</i>	<i>vegfc^{hy} -/- ; vegfd^{-/-} , flt4^{-/-}</i> <i>cxcr4a^{-/-}</i>

The emergence of cardiac lymphatic vessels on the heart has been shown to be correlated with the heart rate increase during the larval to the juvenile transition [34]. Reducing heart rate with the β -blocker Atenolol attenuates cardiac lymphatic sprouts on the BA and impacts the BA lymphatic branch. The BA is the fish cardiac outflow tract with a special thick-wall chamber to adjust the blood flow pressure from the fish ventricle [61]. The sprouts on the BA continue to develop and expand to form an extensive lymphatic network by eight weeks post-fertilization (wpf) [33,34]. The cardiac lymphatic vessels on the BA remain stable and do not bud from this until young adult stages when the LECs emerge onto the heart ventricle around 12–16 wpf (Figure 1a,b). These cells migrate and form vessels along the main coronary arteries, verified by *dll4*, *kdr1*, *flt1*, and *cxcr4a* expression, and also within subepicardial fat tissue [33,34]. The functional significance of this expansion into adipocytes is not known, but interestingly an upregulation of lipid metabolism genes occurs in cardiac lymphatic defective zebrafish, indicating that lymphatic vessels in zebrafish may also have a role in lipid flux in cardiac tissue [60]. Zebrafish cardiac lymphatic vessels do not appear to have open connections with the blood vasculature in resting states, as confirmed by intravascular injection [34]. However, if such connections exist and open under stress remains to be determined.

The development of zebrafish cardiac lymphatic vessels is dependent on Vegfc-Flt4 signaling [33,34,60] (Table 1). The deletion of the *flt4* receptor completely blocks the emergence of cardiac LECs on both BA and heart ventricles [34]. Since *vegfc* mutation is embryonic lethal in zebrafish, cardiac lymphatic vessel dependence on Vegfc was characterized in *vegfc* heterozygotes. The reduction of Vegfc ligand dramatically affected the lymphatic coverage and branching on BA. The sprouts and growth were reduced in the *vegfc* heterozygotes [34] (Table 1). Similar results were observed in hypomorphic *vegfc* mutants on a *vegfd* mutant background [60]. Cardiac lymphatic vessels were still detectable on the BA in zebrafish with either one functional *vegfc* or *vegfd* allele but lacking on heart ventricles of these zebrafish. In hypomorphic *vegfc* and amorphic *vegfd* double mutants, the cardiac lymphatic vessels were absent on both BA and heart ventricles [60]. In order to investigate the role of Vegfc signaling in cardiac lymphatic vessel extension in isolation of the more systemic effects on lymphatic development at earlier stages, Harrison et al. blocked the Vegfc signaling by a heat-inducible expression of soluble Flt4 (sFlt4) receptor [33]. The induction of *sflt4* after the establishment of cardiac lymphatic vessels on BA resulted in no lymphatic vessel formation on the zebrafish ventricle. This indicates that the ventricular extension of the lymphatic vessels specifically requires Vegfc signaling and addition to any prior requirement in the specification. The coronary vessels are also required for normal cardiac lymphatic vessel

extension of the lymphatic vessels specifically requires Vegfc signaling and addition to any prior requirement in the specification. The coronary vessels are also required for normal cardiac lymphatic vessel growth providing a scaffold that can promote the extension of the lymphatic vessels onto the ventricle [33,34]. Phenylhydrazine hydrochloride (PHZ)-induced coronary vasculature overgrowth also promoted cardiac lymphatic development in zebrafish [34]. In contrast, in *cxcr4a* mutants without normal coronary vasculature, the growth of cardiac lymphatic vessels was also blocked on the ventricles [33,34]. Notably, the VFL and cardiac lymphatic vessels on the BA did not show obvious defects in mutants, indicating that the lack of cardiac lymphatic vessels extension onto the heart ventricle is mainly due to the loss of coronary vasculature [33,34].




Figure 1. Cardiac lymphatic vessel development and regeneration. (a) Cardiac lymphatic vessels (*flt4+*, *lyve1b+*, *prox1a+*) that reside on bulbus arteriosus (BA) start to migrate down to the ventricle after 3 months post-fertilization (mpf) when juvenile fish mature to adults. (b) Cardiac lymphatic vessels follow the course of the coronary artery to populate the ventricle. (c) Lymphatic activation during heart regeneration. After cryoinjury, the lymphatic vasculature starts to migrate into the wound at 14 days post-cryoinjury (dpc), over the wound site and is crucial for supporting the regenerative response.

The Role of the Cardiac Lymphatic System in Heart Homeostasis, Disease, and Regeneration

4. The Role of the Cardiac Lymphatic System in Heart Homeostasis, Disease, and Regeneration

The lymphatic vessels play a prominent role in lipid metabolism. Intestinal lymphatic vessels play a prominent role in lipid metabolism. Intestinal lymphatics take up dietary lipids in the form of lipoprotein particles known as chylomicrons to transport them to the bloodstream [62]. Furthermore, lymphatic endothelium is a passive exchange perimeter indispensable for the transport of cholesterol [63]. Although vascular smooth muscle cells are the major cell type responsible for plaque formation in murine models of atherosclerosis contributing to almost 70% of all plaque cells [64], the hypothesis that atherosclerosis is a chronic inflammatory disease of the arterial wall has gained widespread acceptance [65]. Elevated serum cholesterol levels and hypertension are very well-known risk factors for cardiovascular disease [66]. Despite the fact that blood vessels are more frequent than lymphatics in the collagenous outside (*adventitia*) surrounding a coronary plaque, the lymphatic vessels are highly present in the inner layers (*intima* and *media*) of progressive atherosclerotic lesions of coronary arteries and their growth is associated with areas characterized by scattered calcium deposits and cholesterol crystals [67]. In addition,

it has been shown that the specific blockage of the VEGFR-3 decreases lymphatic vessel activation and local cardiac inflammation after transplantation and could be used as a novel lymphatic vessel-targeted immunomodulatory therapy [68]. A better understanding of the cardiac lymphatic system may offer new possibilities for therapeutic interventions in the future.

The blockage of coronary arteries by an atherosclerotic plaque results in the death of surrounding cardiac muscle in events known as myocardial infarction (MI). The necrotic tissue will further cause acute inflammation response, edema and tissue remodeling at the infarcted site, leading to fibrotic scar, arrhythmia and eventually heart failure [69]. Recently, an increasing number of studies have demonstrated the importance of cardiac lymphatic vessels in MI. The lymphangiogenesis at the infarcted area has been observed in artery ligation induced MI mice [32] and rats [70] and in post-MI human patient samples [71]. It has been shown that cardiac lymphatic vasculature has a protective role in post-MI recovery in mice [72–74]. The blockage of VEGF-C signaling by soluble decoy VEGFR3 (sVEGFR3) results in impaired morphology of cardiac lymphatic vessels [72]. The survival rate in sVEGFR3 mice after MI was dramatically reduced compared to wildtype (WT) controls. Further analysis revealed an increase in scar size and intramyocardial hemorrhages in sVEGFR3 mice. Furthermore, the scar composition measured by non-invasive MRI in sVEGFR3 mice was found different from that of WT controls. Apelin (APLN), the ligand for the G-protein-coupled APJ receptor, is important for lymphatic vasculature maturation [75]. The knockout of apelin in mice affected the cell–cell junction integrity in LECs and resulted in dilated lymphatic vessels [73]. Without healthy cardiac lymphatic vasculature, apelin knockout mice suffered a more serious inflammation response after MI.

One of the important functions of lymphatic vessels is immune cell clearance at the inflammation site, which has been shown to be essential for cardiac function after MI [74]. *Lyve-1* deletion in mice did not affect the overall development of lymphatic vessels [76] but was deleterious to leukocyte docking [77]. The *Lyve-1* mutant mice with defective immune cell clearance exhibited more fibrotic tissue and reduced percentage LV ejection fraction and stroke volume in the hearts after MI [74].

Besides its physiologic function in MI, the cardiac lymphatic vessels also secrete signal molecules in regulating heart repair. Lui et al. have shown that Reelin (RELN), an extracellular matrix protein mainly expressed by cardiac LECs, regulates heart growth and promotes cardiomyocyte (CM) proliferation during development in mice hearts [78]. During heart repair in neonatal mice, *Reln* expression was highly induced at the injury site [78]. The deletion of RELN diminished the heart repair with increased scar size and reduced heart function [78]. Consistent with its role in heart development, CM proliferation was reduced and CM apoptosis elevated in *Reln* mutants after MI. Together these studies suggest cardiac lymphatic vessels have a supportive role in post-MI recovery.

Therapeutic induction of cardiac lymphangiogenesis by VEGF-C appears to have a beneficial role in MI. The application of VEGF-C promoted lymphangiogenesis and improved cardiac function in both rats [70] and mice [32] after MI. In VEGF-C-treated rats, immune cell clearance was increased, and cardiac edema and collagen deposition were decreased compared to controls [70]. The potential roles of cardiac lymphatic vessels in heart disease and regeneration are summarized in Figure 2.




Figure 2. The roles of the cardiac lymphatic system in heart disease and regeneration. Coronary artery occlusion by atherosclerotic plaque causes myocardial infarction. The plaque is composed of infiltrated macrophage and cholesterol deposits; cardiac lymphatics running along the artery provide a conduit for cholesterol as a β HDL complex to be removed from the heart and returned to the liver (boxed area). During development, homeostasis and disease, the cardiac lymphatics uptake cell debris, macromolecules, immune cells, pathogens and fluid. Insufficiency of such removal can result in inflammation and edema induced fibrosis, which is detrimental for clinical outcomes. The lymphatic vasculature responds to such injury by an expansion of the lymphatic vascular tree to such a degree that the expansion of the lymphatic capillaries and the damage to the endothelium of lymphatic vessels that prevents a regeneration and growth of the myocardial tissue promote regeneration and growth of the myocardial tissue.

4.2. The Function of Cardiac Lymphatics in Zebrafish Heart Regeneration

Compared to mammals, zebrafish have the amazing capacity to fully regenerate heart tissue after injury, making it an ideal model to study the function of cardiac lymphatic vessels in heart regeneration [79]. Cardiac lymphatics have been shown to have distinct responses in different injury models [33,34]. After amputation, few hearts had limited cardiac lymphatic vessel growth into the wound area during heart regeneration [33,60]. The amputation has less inflammation and only minor collagen/fibrin deposition due to clean removal of the cardiac tissue. In contrast, a dramatic lymphangiogenesis response was induced in zebrafish hearts after cryoinjury, with a large number of lymphatic vessels migrating into the wound area and forming a network with increased branches and enlarged vessel diameter [33,34]. Compared to amputation, cryoinjury is a more complex heart regeneration model, which incorporates components of necrosis and inflammation, with injured tissue and ECM persisting in the wound area. A similar response occurs with injury to the fin suggesting necrotic tissue is important for neo-lymphatic growth after injury [60]. The lymphangiogenic response during heart regeneration is also regulated by *Vegfc*-Flt4 signaling. *Vegfc* expression in zebrafish heart became undetectable 14 days post-amputation (dpa) while still remaining in the heart wound area after 42 days post-amputation (dpc) [33]. In addition, cardiac lymphatic vessel growth was completely absent in *flt4* mutants and highly reduced in *vegfc* hets after cryoinjury [34]. Consistent with this lymphangiogenic response, cardiac lymphatic vessels also show important roles

in heart regeneration after cryoinjury. In the hearts with defective cardiac lymphatic vessel development, heart regeneration after cryoinjury was also impacted compared to WT controls; this was not seen in the heart without cardiac lymphatic vessels after amputation [33,34,60]. The difference in zebrafish heart regeneration after amputation and cryoinjury suggests that cryoinjury may be a more suitable injury model to study the functions of cardiac lymphatic vessels since there are severe inflammation and necrotic tissue at infarctional sites in post-MI human hearts [69].

The functions of zebrafish cardiac lymphatic vessels in cryoinjury appear to include homeostasis maintenance and immune cell clearance. The cardiac lymphatic vessels were able to absorb intramyocardial injected Qdots (<10 nm diameter) and transport *mpx*⁺ neutrophils recruited after cryoinjury [33]. However, *mpx*⁺ neutrophil clearance was attenuated in zebrafish heart without cardiac lymphatic vessels after cryoinjury [33]. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, which detects DNA breaks in apoptosis, revealed an accumulation of TUNEL-positive signals at the infarcted area in cardiac lymphatic vessel impacted hearts in zebrafish [60]. These results indicate that the functions of cardiac lymphatic vessels in immune cell clearance and necrotic cell removal are essential for efficient heart regeneration after cryoinjury in zebrafish. This suggests a therapeutic benefit in targeting a patient's cardiac lymphatic vessels after MI. According to zebrafish heart regeneration results, the induction of cardiac lymphangiogenesis after MI may prevent long-term inflammation and fibrotic scar deposition. It will be interesting to investigate further the dysregulation of myocardial metabolism in the zebrafish lacking cardiac lymphatics and potential effects on myocardial proliferation and regeneration.

5. Future Directions

The zebrafish is an emerging model to study development, regeneration, and model human disease due to their amenability for imaging and available forward and reverse genetic tools. The studies of trunk lymphatic vessels in zebrafish embryos have provided valuable insights into lymphatic development. Different organs, including the heart, may utilize organ/tissue-specific mechanisms to regulate fluid homeostasis and immune cell modulation to accommodate their physiological demands, and this is currently under intense study. For the roles of cardiac lymphatic vessels, the following aspects can be further clarified and studied.

5.1. Cardiac Lymphatic Formation and Populations

We and others have performed a detailed characterization of cardiac lymphatic vessel development and neo-lymphangiogenesis during zebrafish heart regeneration as a basis for future studies. One unexpected aspect of the cardiac lymphatic vessels in zebrafish is their discontinuous nature over the ventricle. A conduit is formed as observed with Qdot uptake following intramyocardial injection [33], but also individual or small groups of LECs were often observed in connection with the main cardiac lymphatic vessel or isolated from it [33,34,60]. Interestingly, Gancz et al. found that this population has a different sensitivity to signaling changes suggesting that isolated cells may not require the scaffold of the coronary arteries. Furthermore, additional signaling pathways and sources may be directing cardiac lymphatic development. Understanding the development of cardiac lymphatic vessels at the cellular level and the signaling that shapes them will be critical to therapeutically encourage (or discourage) their formation.

It remains unclear whether these isolated lymphatic cells and clusters are truly a distinct population or if they are an artifact of the formation of this delicate lymphatic vessel. They may reciprocally dissociate and associate from the main vessel as it expands during development and regeneration. This is consistent with the observed reduced sensitivity of isolated LECs to loss of *cxcr4a*, which manifests as a range of phenotypic severity [33,80]. In *cxcr4a* mutant zebrafish that develop some coronary vasculature, this may be sufficient to support limited LEC outgrowth and expansion but still insufficient for complete vessel

formation. Significantly, these isolated LEC clusters were transiently observed in mouse embryonic hearts, but the origins of the clusters were found to be indistinguishable from the main vessel [34]. This suggests that the LEC clusters could be derived from the main lymphatic vessel in a process that may be similar to that observed during lung development [81]. The clusters are transient in the mouse, not being identifiable at later stages. As the development of the cardiac vessel progresses, these clusters may progressively fuse with the main vessel.

Regardless of origin, it is also possible that isolated LEC populations can contribute to heart regeneration. They appear in zebrafish heart during regeneration after cryoinjury [34]. Furthermore, the identification of the first lymphangiocrine, RELN, suggests that the positive benefits post-MI are not limited to the lymphatics acting as a conduit in the classical sense [78]. Individual cells could excrete pro-regenerative factors or provide scavenger functions much like those described of brain LECs/fluorescent granular perithelial cells [82,83]. It will be fascinating to further uncover the unexpected support functions and morphogenic events of LECs in developmental and regenerative contexts.

5.2. Signaling Pathways Regulating Cardiac Lymphatic Vessel Expansion

Many different signaling pathways emanating from coronary vasculature or otherwise might be further explored. One candidate signaling pathway is Notch, which is known to regulate EC proliferation, motility, filopodia formation, adhesion, and vessel stabilization [84]. Notch receptors and ligands such as Notch1 and Dll4 are predominantly expressed in arterial endothelial cells during embryonic development and arterial cell specification [85,86]. Activation of Notch 1 by Dll4-positive venous ECs (VECs) has been shown to induce a lymphatic transcription profile and so transcriptional activation of Notch signaling may be required to reprogram VEC into LEC [87]. Moreover, genetic targeting of Notch impaired LEC migration during embryonic zebrafish development [87] and blocking its activation by *Dll4*-expression leads to downregulation of *Lyve1* and *EphrinB2* both in vitro [42] and in vivo [88]. Conversely, the lack of Notch activity resulted also in enhanced lymphatic sprouting leading to an increased LEC proliferation/survival in mice [89,90]. The role of Notch signaling in cardiac LECs is less well understood and will require further study.

5.3. Role of Cardiac Lymphatics in Myocardial Infarction

A key role of lymphatic vasculature is the clearance of interstitial fluid. Loss of cardiac lymphatic vessels on the ventricle did not appear to give rise to overt interstitial edema [33,34,60]. Only with loss of *vegfd* together with compromised *Vegfc* function was hypertrophy observed, but it is not clear if this is caused by interstitial edema. In most conditions of compromised *Vegfc*-*Flt4* and/or coronary vessel signaling, the BA lymphatic vessels remain largely unaffected, and this may be sufficient to provide a conduit for fluid removal. It remains to be determined if the hypertrophy observed in the *vegfc* hypermorph; *vegfd* double mutant (*vegfc^{hy}-/-*; *vegfd^{-/-}*) is due to loss of the BA populations, misregulation of *Flt4*/*Vegfr3*-independent signaling or a compensatory effect of earlier reductions in cardiomyocyte proliferation due to loss of mitogens as observed in the mouse [78]. The phenotypic variability observed with the *vegfc^{hy}-/-*; *vegfd^{-/-}* combination, indeed all the variability in reported phenotypes across the three studies using various mutant alleles and reporters, needs to be considered in light of varying modifiers in the genetic background [91].

The damage to heart tissue that occurs in response to MI is complex, involving hypoxia, necrosis, inflammation and fibrosis. The cryoinjury model of zebrafish heart incorporates these features more robustly than the amputation injury. Complexity in a model can occlude analysis of specific processes; however, the cost of this simplicity is that not all features of the regenerative response are captured with the amputation model. In amputation, there is a lack of lymphangiogenesis, and the regenerative response is not perturbed with loss of lymphatics on the ventricle, both, however, are observed after cryoinjury [33,34,60].

Comparison of the models provides a useful insight into which processes are driving the expansion of lymphatic vessels, their roles at the wound site and how these can be utilized to resolve the complex post-MI environment observed in patients.

Author Contributions: X.F., S.T., C.A.P., C.-L.L., and M.R.M.H. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NIH (1R01HL148706), DOD (W81XWH19-1-0359) and TRDRP (T30IP1028) to CLL.

Data Availability Statement: Data sharing not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Natale, G.; Bocci, G.; Ribatti, D. Scholars and scientists in the history of the lymphatic system. *J. Anat.* **2017**, *231*, 417–429.
- Oliver, G.; Kipnis, J.; Randolph, G.J.; Harvey, N.L. The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease. *Cell* **2020**, *182*, 270–296.
- Brouillard, P.; Boon, L.; Vikkula, M. Genetics of lymphatic anomalies. *J. Clin. Investig.* **2014**, *124*, 898–904.
- Rockson, S.G. Lymphedema. *Am. J. Med.* **2001**, *110*, 288–295.
- Randolph, G.J.; Ivanov, S.; Zinselmeyer, B.H.; Scallan, J.P. The lymphatic system: Integral roles in immunity. *Annu. Rev. Immunol.* **2017**, *35*, 31–52.
- Bogoslowski, A.; Butcher, E.C.; Kubes, P. Neutrophils recruited through high endothelial venules of the lymph nodes via PNAd intercept disseminating *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 2449–2454. [[CrossRef](#)]
- Takeda, A.; Hollmén, M.; Dermadi, D.; Pan, J.; Brulois, K.F.; Kaukonen, R.; Lönnberg, T.; Boström, P.; Koskivuo, I.; Irjala, H.; et al. Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils. *Immunity* **2019**, *51*, 561–572. [[CrossRef](#)]
- Bernier-Latmani, J.; Petrova, T. V Intestinal lymphatic vasculature: Structure, mechanisms and functions. *Nat. Publ. Gr.* **2017**, *14*. [[CrossRef](#)]
- Harvey, N.L.; Srinivasan, R.S.; Dillard, M.E.; Johnson, N.C.; Witte, M.H.; Boyd, K.; Sleeman, M.W.; Oliver, G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. *Nat. Genet.* **2005**, *37*, 1072–1081. [[CrossRef](#)]
- Escobedo, N.; Proulx, S.; Karaman, S.; Dillard, M.E.; Johnson, N.; Detmar, M.; Oliver, G. undefined Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice. *JCI Insight* **2016**, *1*, 85096. [[CrossRef](#)]
- Kampmeier, O.F. *Evolution and Comparative Morphology of the Lymphatic System*; Charles C Thomas: Springfield, IL, USA, 1971; Volume 64, ISBN 9780398009663.
- Romer, A.S. *The Vertebrate Body*; W.B. Saunders: Philadelphia, PA, USA, 1977; ISBN 0721676685.
- Peyrot, S.M.; Martin, B.L.; Harland, R.M. Lymph heart musculature is under distinct developmental control from lymphatic endothelium. *Dev. Biol.* **2010**, *339*, 429–438. [[CrossRef](#)]
- Steffensen, J.F.; Lomholt, J.P. The secondary vascular system. In *Fish Physiology*; Academic Press: Cambridge, MA, USA, 1992; Volume 12, pp. 185–217.
- Küchler, A.M.; Gjini, E.; Peterson-Maduro, J.; Cancelli, B.; Wolburg, H.; Schulte-Merker, S. Development of the Zebrafish Lymphatic System Requires Vegf Signaling. *Curr. Biol.* **2006**, *16*, 1244–1248. [[CrossRef](#)]
- Yaniv, K.; Isogai, S.; Castranova, D.; Dye, L.; Hitomi, J.; Weinstein, B.M. Live imaging of lymphatic development in the zebrafish. *Nat. Med.* **2006**, *12*, 711–716. [[CrossRef](#)]
- Shin, M.; Nozaki, T.; Idriji, F.; Isogai, S.; Ogasawara, K.; Ishida, K.; Yuge, S.; Roscoe, B.; Wolfe, S.A.; Fukuhara, S.; et al. Valves Are a Conserved Feature of the Zebrafish Lymphatic System. *Dev. Cell* **2019**, *51*, 374–386. [[CrossRef](#)]
- Vogel, W.O.P.; Claviez, M. Vascular Specialization in Fish, but No Evidence for Lymphatics. *Z. Naturforsch. C J. Biosci.* **1981**, *36*, 490–492.
- Vogel, W.O.P. Zebrafish and lymphangiogenesis: A reply. *Anat. Sci. Int.* **2010**, *85*, 118–119.
- Jensen, L.D.E.; Cao, R.; Hedlund, E.M.; Söll, I.; Lundberg, J.O.; Hauptmann, G.; Steffensen, J.F.; Cao, Y. Nitric oxide permits hypoxia-induced lymphatic perfusion by controlling arterial-lymphatic conduits in zebrafish and glass catfish. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 18408–18413. [[CrossRef](#)]
- Isogai, S.; Hitomi, J.; Yaniv, K.; Weinstein, B.M. Zebrafish as a new animal model to study lymphangiogenesis. *Anat. Sci. Int.* **2009**, *84*, 102–111.
- Koltowska, K.; Lagendijk, A.K.; Pichol-Thievend, C.; Fischer, J.C.; Francois, M.; Ober, E.A.; Yap, A.S.; Hogan, B.M. Vegfc Regulates Bipotential Precursor Division and Prox1 Expression to Promote Lymphatic Identity in Zebrafish. *Cell Rep.* **2015**, *13*, 1828–1841. [[CrossRef](#)]
- Shin, M.; Male, I.; Beane, T.J.; Villefranc, J.A.; Kok, F.O.; Zhu, L.J.; Lawson, N.D. Vegfc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors. *Development* **2016**, *143*, 3785–3795. [[CrossRef](#)]

24. Nicenboim, J.; Malkinson, G.; Lupo, T.; Asaf, L.; Sela, Y.; Maysel, O.; Gibbs-Bar, L.; Senderovich, N.; Hashimshony, T.; Shin, M.; et al. Lymphatic vessels arise from specialized angioblasts within a venous niche. *Nature* **2015**, *522*, 56–61. [[CrossRef](#)]
25. Jung, H.M.; Castranova, D.; Swift, M.R.; Pham, V.N.; Venero Galanternik, M.; Isogai, S.; Butler, M.G.; Mulligan, T.S.; Weinstein, B.M. Development of the larval lymphatic system in zebrafish. *Development* **2017**, *144*, 2070–2081. [[CrossRef](#)]
26. Okuda, K.S.; Astin, J.W.; Misa, J.P.; Flores, M.V.; Crosier, K.E.; Crosier, P.S. *lyve1* expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish. *Development* **2012**, *139*, 2381–2391. [[CrossRef](#)]
27. Coffindaffer-Wilson, M.; Craig, M.P.; Hove, J.R. Determination of lymphatic vascular identity and developmental timecourse in zebrafish (*Danio rerio*). *Lymphology* **2011**, *44*, 1–12.
28. Venero Galanternik, M.; Stratman, A.N.; Jung, H.M.; Butler, M.G.; Weinstein, B.M. Building the drains: The lymphatic vasculature in health and disease. *Wiley Interdiscip. Rev. Dev. Biol.* **2016**, *5*, 689–710.
29. Sabin, F.R. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. *Am. J. Anat.* **1902**, *1*, 367–389. [[CrossRef](#)]
30. Wilting, J.; Aref, Y.; Huang, R.; Tomarev, S.I.; Schweigerer, L.; Christ, B.; Valasek, P.; Papoutsis, M. Dual origin of avian lymphatics. *Dev. Biol.* **2006**, *292*, 165–173. [[CrossRef](#)]
31. Kampmeier, O.F. On the lymph flow of the human heart, with reference to the development of the channels and the first appearance, distribution, and physiology of their valves. *Am. Heart J.* **1928**, *4*, 210–222. [[CrossRef](#)]
32. Klotz, L.; Norman, S.; Vieira, J.M.; Masters, M.; Rohling, M.; Dube, K.N.; Bollini, S.; Matsuzaki, F.; Carr, C.A.; Riley, P.R. Cardiac lymphatics are heterogeneous in origin and respond to injury. *Nature* **2015**, *522*, 62–67. [[CrossRef](#)]
33. Harrison, M.R.; Feng, X.; Mo, G.; Aguayo, A.; Villafuerte, J.; Yoshida, T.; Pearson, C.A.; Schulte-Merker, S.; Ching-Ling, L. Late developing cardiac lymphatic vasculature supports adult zebrafish heart function and regeneration. *eLife* **2019**, *8*. [[CrossRef](#)]
34. Gancz, D.; Raftrey, B.C.; Perlmoter, G.; Marín-Juez, R.; Semo, J.; Matsuoka, R.L.; Karra, R.; Raviv, H.; Moshe, N.; Addadi, Y.; et al. Distinct origins and molecular mechanisms contribute to lymphatic formation during cardiac growth and regeneration. *eLife* **2019**, *8*. [[CrossRef](#)]
35. Ratajska, A.; Gula, G.; Flaht-Zabost, A.; Czarnowska, E.; Cizek, B.; Jankowska-Steifer, E.; Niderla-Bielinska, J.; Radomska-Lesniewska, D. Comparative and Developmental Anatomy of Cardiac Lymphatics. *Sci. World J.* **2014**. [[CrossRef](#)]
36. Srinivasan, R.S.; Dillard, M.E.; Lagutin, O.V.; Lin, F.J.; Tsai, S.; Tsai, M.J.; Samokhvalov, I.M.; Oliver, G. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. *Genes Dev.* **2007**, *21*, 2422–2432. [[CrossRef](#)]
37. Martinez-Corral, I.; Ulvmar, M.H.; Stanczuk, L.; Tatin, F.; Kizhatil, K.; John, S.W.M.; Alitalo, K.; Ortega, S.; Makinen, T. Nonvenous origin of dermal lymphatic vasculature. *Circ. Res.* **2015**, *116*, 1649–1654. [[CrossRef](#)]
38. Stanczuk, L.; Martinez-Corral, I.; Ulvmar, M.H.; Zhang, Y.; Laviña, B.; Fruttiger, M.; Adams, R.H.; Saur, D.; Betsholtz, C.; Ortega, S.; et al. CKIT lineage hemogenic endothelium-derived cells contribute to mesenteric lymphatic vessels. *Cell Rep.* **2015**, *10*, 1708–1721. [[CrossRef](#)]
39. Lioux, G.; Liu, X.; Temiño, S.; Oxendine, M.; Ayala, E.; Ortega, S.; Kelly, R.G.; Oliver, G.; Torres, M. A Second Heart Field-Derived Vasculogenic Niche Contributes to Cardiac Lymphatics. *Dev. Cell* **2020**, *52*, 350–363. [[CrossRef](#)]
40. Maruyama, K.; Miyagawa-Tomita, S.; Mizukami, K.; Matsuzaki, F.; Kurihara, H. *Isl1*-expressing non-venous cell lineage contributes to cardiac lymphatic vessel development. *Dev. Biol.* **2019**, *452*, 134–143. [[CrossRef](#)]
41. Eng, T.C.; Chen, W.; Okuda, K.S.; Misa, J.P.; Padberg, Y.; Crosier, K.E.; Crosier, P.S.; Hall, C.J.; Schulte-Merker, S.; Hogan, B.M.; et al. Zebrafish facial lymphatics develop through sequential addition of venous and non-venous progenitors. *EMBO Rep.* **2019**, *20*. [[CrossRef](#)]
42. Kang, J.; Yoo, J.; Lee, S.; Tang, W.; Aguilar, B.; Ramu, S.; Choi, I.; Otu, H.H.; Shin, J.W.; Dotto, G.P.; et al. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. *Blood* **2010**, *116*, 140–150. [[CrossRef](#)]
43. You, L.R.; Lin, F.J.; Lee, C.T.; DeMayo, F.J.; Tsai, M.J.; Tsai, S.Y. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature* **2005**, *435*, 98–104. [[CrossRef](#)]
44. Johnson, N.C.; Dillard, M.E.; Baluk, P.; McDonald, D.M.; Harvey, N.L.; Frase, S.L.; Oliver, G. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. *Genes Dev.* **2008**, *22*, 3282–3291.
45. Wigle, J.T.; Harvey, N.; Detmar, M.; Lagutina, I.; Grosveld, G.; Gunn, M.D.; Jackson, D.G.; Oliver, G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J.* **2002**, *21*, 1505–1513.
46. François, M.; Caprini, A.; Hosking, B.; Orsenigo, F.; Wilhelm, D.; Browne, C.; Paavonen, K.; Karnezis, T.; Shayan, R.; Downes, M.; et al. Sox18 induces development of the lymphatic vasculature in mice. *Nature* **2008**, *456*, 643–647.
47. Srinivasan, R.S.; Geng, X.; Yang, Y.; Wang, Y.; Mukatira, S.; Studer, M.; Porto, M.P.R.; Lagutin, O.; Oliver, G. The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. *Genes Dev.* **2010**, *24*, 696–707.
48. Kazenwadel, J.; Secker, G.A.; Liu, Y.J.; Rosenfeld, J.A.; Wildin, R.S.; Cuellar-Rodriguez, J.; Hsu, A.P.; Dyack, S.; Fernandez, C.V.; Chong, C.E.; et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. *Blood* **2012**, *119*, 1283–1291.
49. Kazenwadel, J.; Betterman, K.L.; Chong, C.E.; Stokes, P.H.; Lee, Y.K.; Secker, G.A.; Agalarov, Y.; Demir, C.S.; Lawrence, D.M.; Sutton, D.L.; et al. GATA2 is required for lymphatic vessel valve development and maintenance. *J. Clin. Investig.* **2015**, *125*, 2879–2994.

50. Gauvrit, S.; Villasenor, A.; Strilic, B.; Kitchen, P.; Collins, M.M.; Marín-Juez, R.; Guenther, S.; Maischein, H.M.; Fukuda, N.; Canham, M.A.; et al. HHEX is a transcriptional regulator of the VEGFC/FLT4/PROX1 signaling axis during vascular development. *Nat. Commun.* **2018**, *9*, 1–4.
51. Karkkainen, M.J.; Haiko, P.; Sainio, K.; Partanen, J.; Taipale, J.; Petrova, T.V.; Jeltsch, M.; Jackson, D.G.; Talikka, M.; Rauvala, H.; et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat. Immunol.* **2004**, *5*, 74–80. [[CrossRef](#)]
52. Xu, Y.; Yuan, L.; Mak, J.; Pardanaud, L.; Caunt, M.; Kasman, I.; Larrivée, B.; Del Toro, R.; Suchting, S.; Medvinsky, A.; et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. *J. Cell Biol.* **2010**, *188*, 115–130.
53. Wirzenius, M.; Tammela, T.; Uutela, M.; He, Y.; Odorisio, T.; Zambruno, G.; Nagy, J.A.; Dvorak, H.F.; Ylä-Herttuala, S.; Shibuya, M.; et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. *J. Exp. Med.* **2007**, *204*, 1431–1440.
54. Veikkola, T.; Jussila, L.; Makinen, T.; Karpanen, T.; Jeltsch, M.; Petrova, T.V.; Kubo, H.; Thurston, G.; McDonald, D.M.; Achen, M.G.; et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *EMBO J.* **2001**, *20*, 1223–1231.
55. He, Y.; Rajantie, I.; Pajusola, K.; Jeltsch, M.; Holopainen, T.; Ylä-Herttuala, S.; Harding, T.; Jooss, K.; Takahashi, T.; Alitalo, K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. *Cancer Res.* **2005**, *65*, 4739–4746.
56. Jurisic, G.; Detmar, M. Lymphatic endothelium in health and disease. *Cell Tissue Res.* **2009**, *335*, 97–108.
57. Maby-El Hajjami, H.; Petrova, T.V. Developmental and pathological lymphangiogenesis: From models to human disease. *Histochem. Cell Biol.* **2008**, *130*, 1063–1078.
58. Hogan, B.M.; Herpers, R.; Witte, M.; Heloterä, H.; Alitalo, K.; Duckers, H.J.; Schulte-Merker, S. Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. *Development* **2009**, *136*, 4001–4009.
59. van Impel, A.; Zhao, Z.; Hermkens, D.M.A.; Roukens, M.G.; Fischer, J.C.; Peterson-Maduro, J.; Duckers, H.; Ober, E.A.; Ingham, P.W.; Schulte-Merker, S. Divergence of zebrafish and mouse lymphatic cell fate specification pathways. *Development* **2014**, *141*, 1228–1238.
60. Vivien, C.J.; Pichol-Thievend, C.; Sim, C.B.; Smith, J.B.; Bower, N.I.; Hogan, B.M.; Hudson, J.E.; Francois, M.; Porrello, E.R. Vegfc/d-dependent regulation of the lymphatic vasculature during cardiac regeneration is influenced by injury context. *NPJ Regen. Med.* **2019**, *4*, 18.
61. Guerrero, A.; Icardo, J.M.; Durán, A.C.; Gallego, A.; Domezain, A.; Colvee, E.; Sans-Coma, V. Differentiation of the cardiac outflow tract components in alevins of the sturgeon *Acipenser naccarii* (Osteichthyes, Acipenseriformes): Implications for heart evolution. *J. Morphol.* **2004**, *260*, 172–183.
62. Harvey, N.L. The link between lymphatic function and adipose biology. *Ann. N. Y. Acad. Sci.* **2008**, *1131*, 82–88.
63. Lim, H.Y.; Thiam, C.H.; Yeo, K.P.; Bisoesndial, R.; Hii, C.S.; McGrath, K.C.Y.; Tan, K.W.; Heather, A.; Alexander, J.S.J.; Angeli, V. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-Mediated transport of HDL. *Cell Metab.* **2013**, *17*, 671–684.
64. Gomez, D.; Shankman, L.S.; Nguyen, A.T.; Owens, G.K. Detection of histone modifications at specific gene loci in single cells in histological sections. *Nat. Methods* **2013**, *10*, 171–177.
65. Hansson, G.K.; Nilsson, J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. *Semin. Immunopathol.* **2009**, *31*, 95–101.
66. Kannel, W.B.; Dawber, T.R.; Kagan, A.; Revotskie, N.; Stokes, J. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. *Ann. Intern. Med.* **1961**, *55*, 33–50. [[CrossRef](#)]
67. Kholová, I.; Dragneva, G.; Čermáková, P.; Laidinen, S.; Kaskenpää, N.; Hazes, T.; Čermáková, E.; Šteiner, I.; Ylä-Herttuala, S. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. *Eur. J. Clin. Invest.* **2011**, *41*, 487–497.
68. Nykanen, A.I.; Sandelin, H.; Krebs, R.; Keranen, M.A.I.; Tuuminen, R.; Karpanen, T.; Wu, Y.; Pytowski, B.; Koskinen, P.K.; Ylä-Herttuala, S.; et al. Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts. *Circulation* **2010**, *121*, 1413–1422.
69. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Simoons, M.L.; Chaitman, B.R.; White, H.D. Third universal definition of myocardial infarction. *Nat. Rev. Cardiol.* **2012**, *9*, 620–633.
70. Henri, O.; Pouehe, C.; Houssari, M.; Galas, L.; Nicol, L.; Edwards-Levy, F.; Henry, J.P.; Dumesnil, A.; Boukhalfa, I.; Banquet, S.; et al. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. *Circulation* **2016**, *133*, 1484–1497.
71. Ishikawa, Y.; Akishima-Fukasawa, Y.; Ito, K.; Akasaka, Y.; Tanaka, M.; Shimokawa, R.; Kimura-Matsumoto, M.; Morita, H.; Sato, S.; Kamata, I.; et al. Lymphangiogenesis in myocardial remodelling after infarction. *Histopathology* **2007**, *51*, 345–353.
72. Vuorio, T.; Ylä-Herttuala, E.; Laakkonen, J.P.; Laidinen, S.; Liimatainen, T.; Ylä-Herttuala, S. Downregulation of VEGFR3 signaling alters cardiac lymphatic vessel organization and leads to a higher mortality after acute myocardial infarction. *Sci. Rep.* **2018**, *8*, 1–13.

73. Tatin, F.; Renaud-Gabardos, E.; Godet, A.C.; Hantelys, F.; Pujol, F.; Morfoisse, F.; Calise, D.; Viars, F.; Valet, P.; Masri, B.; et al. Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction. *JCI Insight* **2017**, *2*. [[CrossRef](#)]
74. Vieira, J.M.; Norman, S.; del Campo, C.V.; Cahill, T.J.; Barnette, D.N.; Gunadasa-Rohling, M.; Johnson, L.A.; Greaves, D.R.; Carr, C.A.; Jackson, D.G.; et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. *J. Clin. Investig.* **2018**, *128*. [[CrossRef](#)]
75. Sawane, M.; Kajiya, K.; Kidoya, H.; Takagi, M.; Muramatsu, F.; Takakura, N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. *Diabetes* **2013**, *62*, 1970–1980.
76. Gale, N.W.; Prevo, R.; Espinosa, J.; Ferguson, D.J.; Dominguez, M.G.; Yancopoulos, G.D.; Thurston, G.; Jackson, D.G. Normal Lymphatic Development and Function in Mice Deficient for the Lymphatic Hyaluronan Receptor LYVE-1. *Mol. Cell. Biol.* **2007**, *27*, 595–604.
77. Johnson, L.A.; Banerji, S.; Lawrance, W.; Gileadi, U.; Prota, G.; Holder, K.A.; Roshorn, Y.M.; Hanke, T.; Cerundolo, V.; Gale, N.W.; et al. Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. *Nat. Immunol.* **2017**, *18*, 762–770.
78. Liu, X.; De la Cruz, E.; Gu, X.; Balint, L.; Oxendine-Burns, M.; Terrones, T.; Ma, W.; Kuo, H.H.; Lantz, C.; Bansal, T.; et al. Lymphoangiocrine signals promote cardiac growth and repair. *Nature* **2020**, *588*, 705–711.
79. González-Rosa, J.M.; Burns, C.E.; Burns, C.G. Zebrafish heart regeneration: 15 years of discoveries. *Regeneration* **2017**, *4*, 105–123.
80. Harrison, M.R.M.; Bussmann, J.; Huang, Y.; Zhao, L.; Osorio, A.; Burns, C.G.; Burns, G.E.; Sucof, H.M.; Siekmann, A.F.; Lien, C.L. Chemokine-guided angiogenesis directs coronary vasculature formation in zebrafish. *Dev. Cell* **2015**, *33*, 442–454.
81. Kulkarni, R.M.; Herman, A.; Ikegami, M.; Greenberg, J.M.; Akeson, A.L. Lymphatic ontogeny and effect of hypoplasia in developing lung. *Mech. Dev.* **2011**, *128*, 29–40.
82. Galanternik, M.V.; Castranova, D.; Gore, A.V.; Blewett, N.H.; Jung, H.M.; Stratman, A.N.; Kirby, M.R.; Iben, J.; Miller, M.F.; Kawakami, K.; et al. A novel perivascular cell population in the zebrafish brain. *eLife* **2017**, *6*. [[CrossRef](#)]
83. van Lessen, M.; Shibata-Germanos, S.; van Impel, A.; Hawkins, T.A.; Rihel, J.; Schulte-Merker, S. Intracellular uptake of macromolecules by brain lymphatic endothelial cells during zebrafish embryonic development. *eLife* **2017**, *6*. [[CrossRef](#)]
84. Phng, L.K.; Gerhardt, H. Angiogenesis: A Team Effort Coordinated by Notch. *Dev. Cell* **2009**, *16*, 196–208.
85. Kume, T. Novel insights into the differential functions of Notch ligands in vascular formation. *J. Angiogenes. Res.* **2009**, *1*, 8. [[CrossRef](#)]
86. Gridley, T. Notch signaling in the vasculature. *Curr. Top Dev. Biol.* **2010**, *92*, 277–309.
87. Geudens, I.; Herpers, R.; Hermans, K.; Segura, I.; Ruiz de Almodovar, C.; Bussmann, J.; De Smet, F.; Vandeveldel, W.; Hogan, B.M.; Siekmann, A.; et al. Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. *Arter. Thromb. Vasc. Biol.* **2010**, *30*, 1695–1702.
88. Niessen, K.; Zhang, G.; Ridgway, J.B.; Chen, H.; Kolumam, G.; Siebel, C.W.; Yan, M. The notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. *Blood* **2011**, *118*, 1989–1997.
89. Zheng, W.; Tammela, T.; Yamamoto, M.; Anisimov, A.; Holopainen, T.; Kaijalainen, S.; Karpanen, T.; Lehti, K.; Ylä-Herttuala, S.; Alitalo, K. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. *Blood* **2011**, *118*, 1154–1162.
90. Fatima, A.; Culver, A.; Culver, F.; Liu, T.; Dietz, W.H.; Thomson, B.R.; Hadjantonakis, A.K.; Quaggin, S.E.; Kume, T. Murine Notch1 is required for lymphatic vascular morphogenesis during development. *Dev. Dyn.* **2014**, *243*, 957–964.
91. Crim, M.J.; Lawrence, C. A fish is not a mouse: Understanding differences in background genetics is critical for reproducibility. *Lab Anim.* **2021**, *50*, 19–25.